Do you want to read an article? Please log in or register.
Predominantly Persistent Subretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Macular DiseasesRetinal Diseases
Related content
COMMENTED
Macular DiseasesRetinal Diseases
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Ophthalmology.
Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group
doi: 10.1016/j.ophtha.
Macular Diseases
Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)
JAMA Ophthalmol.
Bavinger JC, Ying GS, Daniel E, Grunwald JE, Maguire MG, Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.
doi: 10.1001/jamaophthalmol.
RECOMMENDED
LensesMacular Diseases
Follow up at 5 Years of Non-Fibrotic Scars in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Ophthalmology.
Daniel E, Ying GS, Kim BJ, Toth CA, Ferris F 3rd, Martin DF, Grunwald JE, Jaffe GJ, Dunaief JL, Pan W, Maguire MG; Comparison of Age-related macular degeneration Treatments Trials
doi: 10.1016/j.ophtha.2018.11.020.
COMMENTED
Macular Diseases
Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial
★ 2
Recommended by
Prof. Dr emer. Josef Flammer, Faculty Member
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
doi: 10.1001/jamaophthalmol.2020.0437.
Macular Diseases
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial
JAMA Ophthalmol.
Ramakrishnan MS, Yu Y, VanderBeek BL
doi: 10.1001/jamaophthalmol.2019.4577.
COMMENTED
Macular Diseases
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results
Ophthalmology.
Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ; FLUID Investigators
doi: 10.1016/j.ophtha.2018.11.025.
Further Publications
Systemic Medication Use and the Incidence and Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Retina
Delu S, Peiying H, Brian L V, Joshua L D, Juan E G, Ebenezer D, Maureen G M, Daniel F M, Gui-Shuang Y, and the CATT Research Group.
doi: 10.1097/IAE.0000000000003075
Macular Diseases
Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial
JAMA Ophthalmol.
Scoles D, Ying GS, Pan W, Hua P, Grunwald JE, Daniel E, Jaffe GJ, Toth CA, Martin DF, Maguire MG, Comparison of AMD Treatments Trials Research Group.
doi: 10.1001/jamaophthalmol.2019.5831.
Macular Diseases
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results
Ophthalmology.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group., Writing Committee:., Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd
doi: 10.1016/j.ophtha.2020.01.029.